ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO795

Tegoprubart Reduced Inflammation in Patients With Amyotrophic Lateral Sclerosis (ALS): Potential Implications for Its Use in the Prevention of Rejection in Kidney Transplant

Session Information

Category: Transplantation

  • 2002 Transplantation: Clinical


  • Perrin, Steven, Eledon Pharmaceuticals, Irvine, California, United States
  • Gill, Alan, ALS Therapeutic Discovery Institute, Boston, Massachusetts, United States
  • Bornstein, Jeffrey D., Eledon Pharmaceuticals, Irvine, California, United States
  • Theilhaber, Joachim, Eledon Pharmaceuticals, Irvine, California, United States

Tegoprubart (AT-1501) is a monoclonal antibody that inhibits CD40 ligand (CD40L); it is expected to downregulate both cell mediated and antibody mediated immunity while also creating a more tolerogenic environment, and preventing antibody class switching, reducing high affinity IgG antibodies. Tegoprubart is currently being evaluated in an ongoing trial in kidney transplant (KT).


Tegoprubart was studied in an open-label, dose-escalating trial in patients with ALS. 54 participants received tegoprubart at doses of 1mg/kg (N=9), 2mg/kg (N=9), 4mg/kg (N=18) or 8mg/kg (N=18) IV every 2 weeks for 6 infusions. Safety and the effect of tegoprubart on inflammatory biomarkers were assessed. Target engagement was measured directly via reduction in CD40L and indirectly using CXCL13, a marker of B cell activation. Pro-inflammatory chemokines and cytokines previously shown to be elevated in ALS patients were assessed, and several of these biomarkers may be relevant to the ongoing studies in KT, notably CXCL9 and CXCL10.


Tegoprubart appeared safe and well tolerated at the doses administered. Target engagement was achieved in a dose dependent fashion. In this population of ALS patients, tegoprubart reduced inflammatory biomarkers with the same dose dependent pattern as target engagement. Importantly for KT, tegoprubart reduced CXCL9 and CXCL10, chemokines reported to be associated with acute allograft rejection.


In a study of patients with ALS, tegoprubart at doses of 4mg/kg and 8mg/kg IV every 2 weeks demonstrated target engagement with an associated reduction in inflammation. Among the inflammatory biomarkers reduced were CXCL9 and CXCL10, positive signals for tegoprubart's ongoing program in KT.


  • Commercial Support